久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • FDA Grants Miltefosine Orphan Drug Designation for Treatment of GAE americanpharmaceuticalreview
    June 29, 2017
    Profounda announced it has received the US Food and Drug Administration's Orphan Drug Designation?for the use of miltefosine to treat Granulomatous Amebic Encephalitis (GAE). Profounda licensed miltefosine (Impavido) from Knight Therapeutics.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service